Profile change history

What changed for Retatrutide?

A deterministic history of records added to PeptideScanner and preserved profile or record revisions connected through the reviewed Retatrutide identity.

29Total events
27Record additions
2Version changes
3Cited source years

Before and after

Preserved version changes

Profile status changed

Retatrutide profile

We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that retatrutide cannot be used in compounding.

PeptideScanner change date
November 14, 2026
Evidence lane
Profile

Status

Before
Investigational
After
In clinical trials; not FDA-approved

Profile summary

Before
A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
After
An experimental GIP, GLP-1 and glucagon receptor agonist from Eli Lilly. FDA says it is not an approved drug and cannot be used in compounding.

Evidence note

Before
ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.
After
Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.

Cited source records

Before
ctg-nct06297603-v25
After
ctg-nct06297603-v25, fda-unapproved-glp1-concerns-2026-r2, journal-pmid-37366315, journal-pmid-37385280, journal-pmid-42250575, ctg-observation-nct05882045-2026-07-30-d21e38ddcccc, ctg-observation-nct05929079-2026-07-30-d0cad2c0ebfa, ctg-observation-nct05929066-2026-08-21-fa2b7b67fa10, ctg-observation-nct06383390-2026-08-24-4bb37a90f79a, ctg-observation-nct06297603-2026-11-13-c86dcf0120ca

Named organizations

Before
Eli Lilly and Company [sources: ctg-nct06297603-v25]
After
Eli Lilly and Company [sources: ctg-nct06297603-v25]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]

Claim citations

Before
name: ctg-nct06297603-v25; aliases: ctg-nct06297603-v25; category: ctg-nct06297603-v25; status: ctg-nct06297603-v25; summary: ctg-nct06297603-v25; evidenceNote: ctg-nct06297603-v25
After
name: ctg-nct06297603-v25; aliases: ctg-nct06297603-v25; category: ctg-nct06297603-v25; status: ctg-nct06297603-v25, ctg-observation-nct06297603-2026-11-13-c86dcf0120ca, fda-unapproved-glp1-concerns-2026-r2; summary: ctg-nct06297603-v25, journal-pmid-42250575, fda-unapproved-glp1-concerns-2026-r2; evidenceNote: journal-pmid-37366315, journal-pmid-42250575, fda-unapproved-glp1-concerns-2026-r2
Profile updated

Retatrutide profile

We rewrote the profile summary to describe the cited study record more directly. The cited source and status did not change.

PeptideScanner change date
July 27, 2026
Evidence lane
Profile

Profile summary

Before
A multi-receptor metabolic candidate with active ClinicalTrials.gov records.
After
A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.

Collection chronology

Evidence added to PeptideScanner

Browse all 27 connected records →

Showing the latest 27 additions by PeptideScanner publication date; the complete connected record set remains available on the cross-source timeline. Most recent addition: November 14, 2026.

Record added

ClinicalTrials.gov record NCT05936151

PeptideScanner retained ClinicalTrials.gov record NCT05936151 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 9, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06297603

PeptideScanner retained ClinicalTrials.gov record NCT06297603 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07035093

PeptideScanner retained ClinicalTrials.gov record NCT07035093 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
November 14, 2026
Cited source date
September 25, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT07232719

PeptideScanner retained ClinicalTrials.gov record NCT07232719 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
November 14, 2026
Cited source date
November 10, 2026
Evidence lane
Clinical trials
Record added

Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2?

PubMed lists PMID 42849462 in Lancet (London, England) as Journal Article, with publication-date metadata of 2026-10-10 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
October 8, 2026
Evidence lane
Literature metadata
Record added

Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain.

PubMed lists PMID 42853576 in JAMA as Journal Article, with publication-date metadata of 2026-11-03 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
November 14, 2026
Cited source date
November 3, 2026
Evidence lane
Literature metadata
Record added

ClinicalTrials.gov record NCT05929066

PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
September 9, 2026
Cited source date
August 21, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT06383390

PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
September 9, 2026
Cited source date
August 24, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05882045

PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
August 14, 2026
Cited source date
July 30, 2026
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT05929079

PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.

PeptideScanner change date
August 14, 2026
Cited source date
July 30, 2026
Evidence lane
Clinical trials
Record added

Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

PubMed lists PMID 37888925 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
July 3, 2025
Evidence lane
Literature metadata
Record added

Triple-Hormone-Receptor Agonist Retatrutide for Obesity.

PubMed lists PMID 37888926 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
July 3, 2025
Evidence lane
Literature metadata
Record added

Triple-Hormone-Receptor Agonist Retatrutide for Obesity. Reply.

PubMed lists PMID 37888927 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2023-10-26 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
July 3, 2025
Evidence lane
Literature metadata
Record added

Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide.

PubMed lists PMID 39019866 in Cell discovery as Letter, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
July 20, 2024
Evidence lane
Literature metadata
Record added

Retatrutide.

PubMed lists PMID 39429457 in Clinical diabetes : a publication of the American Diabetes Association as Journal Article, with publication-date metadata of 2024-08-01 (day precision). PeptideScanner associated the retained record with the identity slug retatrutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

PeptideScanner change date
August 13, 2026
Cited source date
September 2, 2025
Evidence lane
Literature metadata
Record added

PubMed record PMID 39868848

PeptideScanner retained PubMed bibliographic metadata for PMID 39868848 at 2026-07-30T16:31:18.163Z. PubMed recorded a metadata revision date of 2026-01-27 and an Entrez history date of 2025-01-27. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
January 27, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 40735804

PeptideScanner retained PubMed bibliographic metadata for PMID 40735804 at 2026-07-30T16:23:38.757Z. PubMed recorded a metadata revision date of 2026-03-07 and an Entrez history date of 2025-07-30. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 12, 2026
Cited source date
March 7, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 37178114

PeptideScanner retained PubMed bibliographic metadata for PMID 37178114 at 2026-07-30T16:23:33.798Z. PubMed recorded a metadata revision date of 2026-03-27 and an Entrez history date of 2023-05-13. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
March 27, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 41056349

PeptideScanner retained PubMed bibliographic metadata for PMID 41056349 at 2026-07-30T16:20:41.592Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2025-10-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
May 22, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42264536

PeptideScanner retained PubMed bibliographic metadata for PMID 42264536 at 2026-07-30T16:14:18.135Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
June 9, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42425580

PeptideScanner retained PubMed bibliographic metadata for PMID 42425580 at 2026-08-10T18:13:55.212Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2026-07-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 11, 2026
Cited source date
July 9, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 38323122

PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 31, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42493254

PeptideScanner retained PubMed bibliographic metadata for PMID 42493254 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 23, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42527705

PeptideScanner retained PubMed bibliographic metadata for PMID 42527705 at 2026-08-10T18:13:57.053Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
July 29, 2026
Evidence lane
Literature metadata
Record added

PubMed record PMID 42567543

PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.

PeptideScanner change date
August 10, 2026
Cited source date
August 7, 2026
Evidence lane
Literature metadata